MX2011013748A - Anticuerpos biespecificos que se unen a proteinas de complemento. - Google Patents
Anticuerpos biespecificos que se unen a proteinas de complemento.Info
- Publication number
- MX2011013748A MX2011013748A MX2011013748A MX2011013748A MX2011013748A MX 2011013748 A MX2011013748 A MX 2011013748A MX 2011013748 A MX2011013748 A MX 2011013748A MX 2011013748 A MX2011013748 A MX 2011013748A MX 2011013748 A MX2011013748 A MX 2011013748A
- Authority
- MX
- Mexico
- Prior art keywords
- bispecific antibodies
- bind
- complement proteins
- proteins
- complex
- Prior art date
Links
- 102000000989 Complement System Proteins Human genes 0.000 title 1
- 108010069112 Complement System Proteins Proteins 0.000 title 1
- 102100031506 Complement C5 Human genes 0.000 abstract 5
- 101000941598 Homo sapiens Complement C5 Proteins 0.000 abstract 4
- 230000000295 complement effect Effects 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 101800001654 C5a anaphylatoxin Proteins 0.000 abstract 1
- 102100032996 C5a anaphylatoxin chemotactic receptor 2 Human genes 0.000 abstract 1
- 101000868001 Homo sapiens C5a anaphylatoxin chemotactic receptor 2 Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000035605 chemotaxis Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
Abstract
La presente descripción se refiere a anticuerpos biespecíficos que pueden unirse a dos o más diferentes epítopos. Por ejemplo, los anticuerpos biespecíficos descritos aquí pueden unirse a dos o más proteínas diferentes, en donde por lo menos dos de las proteínas se seleccionan de C5a, C5b, un receptor celular para C5a (por ejemplo, C5aR1 ó C5L2), el complejo C5b-9, y un componente de intermediario del complemento terminal tal como C5b-6, C5b-7, o C5b-8. Los anticuerpos biespecíficos descritos aquí son útiles para, por ejemplo, inhibir el complemento terminal (por ejemplo, el ensamble y/o actividad del complejo C5b- 9) y/o inflamación mediada por anafilatoxina C5a (por ejemplo, quimiotaxis mediada por C5a o células inmunes inflamatorias). Por consiguiente, los anticuerpos biespecíficos pueden ser utilizados en métodos para tratar una variedad de trastornos asociados con la trayectoria de complemento.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21964409P | 2009-06-23 | 2009-06-23 | |
| US22800109P | 2009-07-23 | 2009-07-23 | |
| PCT/US2010/039448 WO2010151526A1 (en) | 2009-06-23 | 2010-06-22 | Bispecific antibodies that bind to complement proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011013748A true MX2011013748A (es) | 2012-04-20 |
Family
ID=43386850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011013748A MX2011013748A (es) | 2009-06-23 | 2010-06-22 | Anticuerpos biespecificos que se unen a proteinas de complemento. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110002931A1 (es) |
| EP (1) | EP2445937B1 (es) |
| JP (1) | JP2012531418A (es) |
| KR (1) | KR20120105405A (es) |
| CN (1) | CN102597005A (es) |
| AU (1) | AU2010264520A1 (es) |
| BR (1) | BRPI1012759A2 (es) |
| CA (1) | CA2766565A1 (es) |
| IL (1) | IL217087A0 (es) |
| IN (1) | IN2012DN00424A (es) |
| MX (1) | MX2011013748A (es) |
| NZ (1) | NZ597259A (es) |
| RU (1) | RU2012102021A (es) |
| WO (1) | WO2010151526A1 (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP3056568B1 (en) | 2006-03-31 | 2021-09-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| DK2488203T3 (en) * | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| AU2011223866B2 (en) | 2010-03-01 | 2015-05-21 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating Degos' disease |
| CN103328632A (zh) | 2010-11-30 | 2013-09-25 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| KR20220044616A (ko) | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법 |
| EP2726506A1 (en) * | 2011-05-27 | 2014-05-07 | Dutalys | Removal of monomeric targets |
| EP3524258B1 (en) | 2011-06-22 | 2025-10-01 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| PT2861246T (pt) * | 2012-06-18 | 2021-04-05 | Univ Leicester | Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações |
| CN110818798A (zh) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| RS63212B1 (sr) * | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | Antikomplementna c1s antitela i njihove primene |
| WO2014160129A2 (en) | 2013-03-14 | 2014-10-02 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| WO2014160958A1 (en) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| KR102192596B1 (ko) * | 2013-08-07 | 2020-12-18 | 알렉시온 파마슈티칼스, 인코포레이티드 | 비정형적 용혈성 요독증후군 (ahus) 바이오마커 단백질 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| AR103162A1 (es) | 2014-12-19 | 2017-04-19 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-c5 y métodos para su uso |
| JP2018511557A (ja) * | 2015-01-22 | 2018-04-26 | 中外製薬株式会社 | ２種以上の抗ｃ５抗体の組み合わせおよび使用方法 |
| HUE061076T2 (hu) | 2015-04-06 | 2023-05-28 | Bioverativ Usa Inc | Humanizált anti-C1s ellenanyagok alkalmazási eljárások |
| KR20180020296A (ko) * | 2015-06-26 | 2018-02-27 | 바이오버라티브 유에스에이 인코포레이티드 | 자가면역 및 동종면역 장애를 치료하는 방법 |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| LT3468990T (lt) | 2016-06-14 | 2024-06-25 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antikūnai ir jų panaudojimas |
| DK3525583T3 (da) | 2016-10-12 | 2025-10-27 | Bioverativ Usa Inc | Anti-c1s-antistoffer og fremgangsmåder til anvendelse deraf |
| CN118184777A (zh) | 2017-01-30 | 2024-06-14 | 亚力兄制药公司 | 单价抗备解素抗体及抗体片段 |
| KR102656199B1 (ko) * | 2017-04-21 | 2024-04-09 | 볼루션 이뮤노 파마슈티컬스 에스에이 | 자가면역 수포 질환의 치료를 위한 코버신 |
| CN111201246B (zh) | 2017-07-11 | 2023-10-27 | 亚力兄制药公司 | 结合补体成分c5或血清白蛋白的多肽及其融合蛋白 |
| CN116271012A (zh) | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | 高浓度抗c5抗体制剂 |
| BR112020008182A2 (pt) | 2017-10-26 | 2020-10-27 | Alexion Pharmaceuticals, Inc. | dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua) |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| US11338020B2 (en) | 2018-01-09 | 2022-05-24 | Synthetic Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| EP3773686B1 (en) | 2018-03-20 | 2023-06-07 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| ES3032290T3 (en) | 2018-03-20 | 2025-07-16 | Theriva Biologics Inc | Intestinal alkaline phosphatase formulations |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| EP3586865A1 (en) * | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| JP7538723B2 (ja) | 2018-06-28 | 2024-08-22 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗ｃ５抗体の産生方法 |
| WO2020092549A1 (en) | 2018-10-30 | 2020-05-07 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| CN113993541A (zh) | 2019-05-06 | 2022-01-28 | 合成生物制品有限公司 | 基于碱性磷酸酶的肿瘤学治疗 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| TW202246331A (zh) | 2021-01-13 | 2022-12-01 | 美商威特拉公司 | 人源化補體５ａ受體１抗體及其使用方法 |
| CN116338208A (zh) * | 2023-03-30 | 2023-06-27 | 石河子大学 | 用于母猪早期妊娠诊断的蛋白生物标志物及其应用 |
| CN117380279B (zh) * | 2023-10-13 | 2025-08-15 | 台州学院 | 一种P-ZIF-8/CaIn2S4复合材料及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| NO162210C (no) * | 1987-07-20 | 1989-11-22 | Fasting Biotech As | Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a. |
| US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
| KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| CA2183577C (en) | 1994-03-07 | 2007-10-30 | John S. Patton | Methods and compositions for pulmonary delivery of insulin |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US7056897B2 (en) | 1997-11-03 | 2006-06-06 | The Arizona Board Of Regents | Inducible expression vectors and methods of use thereof |
| WO1999054440A1 (en) | 1998-04-21 | 1999-10-28 | Micromet Gesellschaft Für Biomedizinische Forschung Mbh | CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF |
| KR20000065395A (ko) * | 1999-04-02 | 2000-11-15 | 김영환 | 단전자 트랜지스터의 제조 방법 |
| WO2000061178A1 (en) | 1999-04-13 | 2000-10-19 | Inhale Therapeutics Systems, Inc. | Pulmonary administration of dry powder formulations for treating infertility |
| HK1042234A1 (zh) | 1999-04-13 | 2002-08-09 | Nektar Therapeutics | 向肺部施加乾粉配方以治疗不育症 |
| GB9910975D0 (en) | 1999-05-13 | 1999-07-14 | Univ Strathclyde | Rapid dehydration of proteins |
| US6673346B1 (en) | 1999-08-31 | 2004-01-06 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of sepsis |
| EP1433793A4 (en) | 2001-09-13 | 2006-01-25 | Inst Antibodies Co Ltd | METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY |
| NZ534399A (en) | 2002-01-25 | 2008-08-29 | G2 Therapies Ltd | Monoclonal antibodies against extracellular loops of C5aR |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| AU2003290605A1 (en) | 2002-11-05 | 2004-06-03 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| JP2006518750A (ja) | 2003-02-21 | 2006-08-17 | リクスホスピタレット−ラジウムホスピタレット・ホーエフ | 胎便吸引症候群の治療のための方法および組成物 |
| WO2004103288A2 (en) | 2003-05-13 | 2004-12-02 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Method of preventing recurrent miscarriages |
| CN1787741B (zh) | 2003-05-15 | 2011-08-17 | 唐纳士公司 | 用于预防和治疗败血症的方法与组合物 |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| GB0416328D0 (en) | 2004-07-21 | 2004-08-25 | Univ Cardiff | Use of dry powder compositions for pulmonary delivery |
| EP1819731A4 (en) * | 2004-12-08 | 2013-02-13 | Immunomedics Inc | METHOD AND COMPOSITION FOR IMMUNOTHERAPY AND FOR THE DETECTION OF INFLAMMATORY AND DYSEGRATIVE IMMUNE DISEASES, INFECTION DISEASES, PATHOLOGICAL ANGIOGENESIS AND CANCER |
| JP5838021B2 (ja) | 2005-04-15 | 2015-12-24 | マクロジェニクス，インコーポレーテッド | 共有結合型ダイアボディとその使用 |
| AU2006283532B2 (en) | 2005-08-19 | 2012-04-26 | Abbvie Inc. | Dual variable domain immunoglobin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP2918269A1 (en) * | 2006-03-02 | 2015-09-16 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| US8037880B2 (en) | 2006-04-07 | 2011-10-18 | The University Of Western Ontario | Dry powder inhaler |
| AU2008228247A1 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| AU2009274129B2 (en) * | 2008-07-21 | 2016-02-25 | Immunomedics Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| WO2010030789A1 (en) * | 2008-09-10 | 2010-03-18 | Novelmed Therapeutics, Inc. | Device and method for inhibiting complement activation |
| CN109045296A (zh) * | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
| WO2010057084A1 (en) * | 2008-11-14 | 2010-05-20 | Novelmed Therapeutics, Inc. | Method of treating ischemia reperfusion injury |
-
2010
- 2010-06-22 KR KR1020127001498A patent/KR20120105405A/ko not_active Withdrawn
- 2010-06-22 AU AU2010264520A patent/AU2010264520A1/en not_active Abandoned
- 2010-06-22 CN CN2010800373524A patent/CN102597005A/zh active Pending
- 2010-06-22 US US12/820,654 patent/US20110002931A1/en not_active Abandoned
- 2010-06-22 EP EP10792563.8A patent/EP2445937B1/en active Active
- 2010-06-22 NZ NZ597259A patent/NZ597259A/en not_active IP Right Cessation
- 2010-06-22 RU RU2012102021/10A patent/RU2012102021A/ru unknown
- 2010-06-22 JP JP2012517642A patent/JP2012531418A/ja not_active Withdrawn
- 2010-06-22 MX MX2011013748A patent/MX2011013748A/es not_active Application Discontinuation
- 2010-06-22 CA CA2766565A patent/CA2766565A1/en not_active Abandoned
- 2010-06-22 BR BRPI1012759A patent/BRPI1012759A2/pt not_active IP Right Cessation
- 2010-06-22 WO PCT/US2010/039448 patent/WO2010151526A1/en not_active Ceased
-
2011
- 2011-12-19 IL IL217087A patent/IL217087A0/en unknown
-
2012
- 2012-01-16 IN IN424DEN2012 patent/IN2012DN00424A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110002931A1 (en) | 2011-01-06 |
| BRPI1012759A2 (pt) | 2019-07-02 |
| EP2445937A1 (en) | 2012-05-02 |
| IN2012DN00424A (es) | 2015-05-15 |
| IL217087A0 (en) | 2012-02-29 |
| KR20120105405A (ko) | 2012-09-25 |
| JP2012531418A (ja) | 2012-12-10 |
| EP2445937B1 (en) | 2017-05-24 |
| EP2445937A4 (en) | 2013-06-19 |
| CN102597005A (zh) | 2012-07-18 |
| WO2010151526A1 (en) | 2010-12-29 |
| AU2010264520A1 (en) | 2012-01-19 |
| CA2766565A1 (en) | 2010-12-29 |
| NZ597259A (en) | 2014-04-30 |
| RU2012102021A (ru) | 2013-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011013748A (es) | Anticuerpos biespecificos que se unen a proteinas de complemento. | |
| WO2015127136A3 (en) | Ebola monoclonal antibodies | |
| MX2020004503A (es) | Anticuerpos cd3 humanizados o quimericos. | |
| NZ739028A (en) | Humanized or chimeric cd3 antibodies | |
| HK1243333A1 (zh) | 用於修饰的t细胞的方法和组合物 | |
| WO2015091914A3 (en) | Caninized murine anti-canine pd-1 antibodies | |
| WO2016086175A8 (en) | Effector-deficient anti-cd32a antibodies | |
| MY173899A (en) | Cd3-binding molecules capable of binding to human and non-human cd3 | |
| IL212066A (en) | 4cxcr antibodies, preparations containing them, processes for their production and selection and use for cancer treatment | |
| NZ700650A (en) | Anti-hla-b*27 antibodies and uses thereof | |
| WO2016014688A3 (en) | Anti-pd-1 antibodies | |
| MX362039B (es) | Anticuerpos anti-il-23. | |
| WO2014190356A3 (en) | Anti-b7-h5 antibodies and their uses | |
| WO2016014974A3 (en) | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same | |
| NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
| WO2010129917A3 (en) | Anti-cd100 antibodies and methods for using the same | |
| WO2014164959A3 (en) | Anti-il-33 antibodies and uses thereof | |
| MX347164B (es) | Anticuerpos anti-il-36r. | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| WO2012031099A3 (en) | Anti-cxcl13 antibodies and methods of using the same | |
| MX369148B (es) | Agentes de unión kir3dl2. | |
| WO2012149356A3 (en) | Anti-cd40 antibodies and methods of use | |
| MX2010010387A (es) | Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos. | |
| IN2012DN02196A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |